Market research
D05.F Deciphera Pharmaceuticals, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 66.9
- Dividend yield
- Not available
- Beta
- 0.18
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- US24344T1016
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 66.9
- Dividend yield
- Not available
- Beta
- 0.18
About
About Deciphera Pharmaceuticals, Inc
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts. As of June 11, 2024, Deciphera Pharmaceuticals, Inc. operates as a subsidiary of Ono Pharmaceutical Co., Ltd.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the D05.F discussion.
5 years, 4 months ago
Deciphera Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 26.4% below its 200 day moving average.
From a valuation standpoint, the stock is 95.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 58.4.
Deciphera Pharmaceuticals, Inc's total revenue rose by inf% to $19M since the same quarter in the previous year.
Its net income has increased by 6.7% to $-63M since the same quarter in the previous year.
Finally, its free cash flow grew by 13.9% to $-50M since the same quarter in the previous year.
Based on the above factors, Deciphera Pharmaceuticals, Inc gets an overall score of 4/5.